Ginkgo Bioworks Holdings, Inc. (DNA) News
Filter DNA News Items
DNA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DNA News Highlights
- DNA's 30 day story count now stands at 5.
- Over the past 20 days, the trend for DNA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- CELL, BIO and CPA are the most mentioned tickers in articles about DNA.
Latest DNA News From Around the Web
Below are the latest news stories about GINKGO BIOWORKS HOLDINGS INC that investors may wish to consider to help them evaluate DNA as an investment opportunity.
Ginkgo Bioworks and Centrient Pharmaceuticals Announce Expansion of Partnership Following Success of Initial Project to Bring Sustainable Innovation to the Generic API SpaceCentrient Pharmaceuticals ("Centrient"), the global business-to-business leader in sustainable antibiotics, next-generation statins and anti-fungals, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced they are expanding their existing partnership aimed at broadening Centrient's portfolio of environmentally friendly active pharmaceutical ingredients (APIs), following the success of previous work together. |
Hero or Zero? 3 High-Risk Biotech Stocks to Make You Rich … or Broke.These biotech companies are swinging for the fences. |
DNA Stock Earnings: Ginkgo Bioworks Misses EPS, Beats Revenue EstimatesDNA stock earnings show Ginkgo Bioworks missing analyst estimates for its loss per share but beating revenue estimates. |
Ginkgo Bioworks Reports First Quarter 2023 Financial ResultsGinkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2023. The update, including a webcast slide presentation with additional details on the first quarter and supplemental financial information, will be available at investors.ginkgobioworks.com. |
Octarine Bio and Ginkgo Bioworks Announce Partnership to Produce Natural ColorsOctarine Bio, a synthetic biology company developing new sustainable bio-based ingredients, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a multi-stage partnership focused on compounds in the tryptophan pathway, with the objective of engineering a strain for producing violacein and its derivatives, a naturally occurring bis-indole pigment with potent bioactive properties including anti-microbial, anti-oxidant, and UV |
Ginkgo Bioworks Partners with Boehringer Ingelheim to Develop Breakthrough Therapies for Hard-to-Treat DiseasesGinkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership with Boehringer Ingelheim. The two companies will leverage Ginkgo's natural product discovery capabilities to accelerate the discovery and development of novel therapeutic molecules to address diseases with high unmet patient needs that are out of reach of conventional drug discovery. |
Ginkgo Bioworks Announces Appointment of Steven P. Coen as Chief Accounting OfficerGinkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and biosecurity, today announced the appointment of Steven P. Coen, CPA, a seasoned finance executive with more than 30 years of public accounting and corporate finance leadership experience, as Chief Accounting Officer ("CAO"), effective May 15, 2023. Most recently, Mr. Coen was the Corporate Vice President and Corporate Controller for Charles River Laboratories, a |
Ginkgo Bioworks Announces Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual MeetingGinkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced its participation in the 26th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 16-20, in Los Angeles. Ginkgo will present data on its high-throughput screening platform for chimeric antigen receptor (CAR) libraries, which can enable discovery of CAR variants with desired characteristics. This capability has the potential to discover CAR-T therapeutic candid |
Ginkgo Bioworks Announces Date of First Quarter 2023 Results PresentationGinkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, beginning at 4:30 p.m. ET. |
7 Best Cathie Wood Stocks for Your May 2023 Buy ListThis year promises to be very different for Cathie Wood stocks, as signs of economic improvement become more prominent. |